Nexalin Technology (NXL)

• Market cap: $38.2M
• 1 day: -11.42%
• 5 days: -11.42%
• 1 month: 1.77%
• 3 months: -26.41%
• 6 months: 191.40%
• Year to date: -10.59%
• 1 year: 731.88%
• 5 years: 27.56%
• 10 years: 27.56%
• Sector: Healthcare
• Industry: Electromedical & Electrotherapeutic Apparatus

About: Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Employees: 6

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

257% more capital invested

Capital invested by funds: $287K [Q3] → $1.02M (+$738K) [Q4]

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

20% more funds holding

Funds holding: 15 [Q3] → 18 (+3) [Q4]

1.26% less ownership

Funds ownership: 4.05% [Q3] → 2.79% (-1.26%) [Q4]